In connection with the separation of Becton, Dickinson and Company's (BD) diabetes care business (the Separation) through the distribution of 100% of the outstanding shares of common stock, par value $0.01 per share, of Embecta Corp. (embecta) to BD's stockholders of record as of the close of business on March 22, 2022 (the Distribution), each of Claire Pomeroy, MD and David F. Melcher has resigned as directors of BD, in each case effective as of April 1, 2022, in connection with the completion of the Separation and the Distribution and their appointment to the board of directors of embecta.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
234.4 USD | -2.46% | +2.00% | -3.14% |
01:20pm | TD Cowen Adjusts Price Target on Becton, Dickinson and Company to $260 From $271 | MT |
05-02 | Evercore ISI Raises Becton, Dickinson and Company Price Target to $282 From $280 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.14% | 69.44B | |
-3.72% | 184B | |
-0.71% | 107B | |
+3.64% | 50.37B | |
+9.03% | 44.82B | |
+3.40% | 41.53B | |
+3.42% | 26.84B | |
+3.32% | 26.73B | |
+15.23% | 25.71B | |
-0.10% | 24.34B |
- Stock Market
- Equities
- BDX Stock
- News Becton, Dickinson and Company
- Becton, Dickinson and Company Announces Management Changes